Literature DB >> 11520563

Differential gene expression associated with tumorigenicity of cultured green turtle fibropapilloma-derived fibroblasts.

L H Herbst1, R Chakrabarti, P A Klein, M Achary.   

Abstract

Fibroblast cell lines derived from normal skin and experimentally induced fibropapillomas of green turtles (Chelonia mydas), were propagated in vitro and tested for tumorigenicity in immunodeficient mice. Differential display RT-PCR was used to identify differences in messenger RNA expression between normal and tumorigenic fibropapillomatosis (FP)-derived fibroblasts from the same individual. Four unique products that were apparently overexpresed in FP and three that were apparently underexpressed were cloned and sequenced. Differential expression was confirmed for three products by Northern blotting. Two overexpressed products showed extensive sequence matches to the known mammalian cellular genes, beta-hexosaminidase and chain termination factor. The product that was underexpressed in FP showed homology with mammalian thrombospondin, a known tumor-suppressor gene and an inhibitor of angiogenesis. All of the partial gene sequences identified are novel and will require full length cDNA sequencing to further analyze their identities. These results, however, provide the foundation for further investigation to determine the role of each of these gene products in FP pathogenesis and cellular transformation. The potential for some of these products to serve as biomarkers for FP is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520563     DOI: 10.1016/s0165-4608(01)00421-6

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  Perspectives on the expansion of human precision oncology and genomic approaches to sea turtle fibropapillomatosis.

Authors:  David J Duffy; Mark Q Martindale
Journal:  Commun Biol       Date:  2019-02-07

Review 2.  Wildlife cancer: a conservation perspective.

Authors:  Denise McAloose; Alisa L Newton
Journal:  Nat Rev Cancer       Date:  2009-07       Impact factor: 60.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.